Roth Capital Brokers Raise Earnings Estimates for Zosano Pharma Corp. (ZSAN)
Zosano Pharma Corp. (NASDAQ:ZSAN) – Investment analysts at Roth Capital lifted their FY2016 earnings per share (EPS) estimates for Zosano Pharma Corp. in a research report issued on Tuesday. Roth Capital analyst S. Henry now anticipates that the firm will post earnings per share of ($2.15) for the year, up from their prior forecast of ($2.50). Roth Capital also issued estimates for Zosano Pharma Corp.’s Q4 2016 earnings at ($0.45) EPS, FY2017 earnings at ($0.85) EPS, FY2018 earnings at ($0.75) EPS, FY2019 earnings at ($0.70) EPS and FY2020 earnings at ($0.55) EPS.
Several other brokerages have also weighed in on ZSAN. Zacks Investment Research downgraded shares of Zosano Pharma Corp. from a “hold” rating to a “sell” rating in a research report on Wednesday, August 31st. Ladenburg Thalmann lowered Zosano Pharma Corp. from a “buy” rating to a “neutral” rating in a report on Thursday, August 11th.
Zosano Pharma Corp. (NASDAQ:ZSAN) remained flat at $0.59 during trading on Thursday. The stock had a trading volume of 3,936 shares. The firm’s market cap is $9.92 billion. The company has a 50-day moving average price of $0.64 and a 200 day moving average price of $1.19. Zosano Pharma Corp. has a one year low of $0.45 and a one year high of $3.20.
In related news, major shareholder M James Barrett sold 50,000 shares of the stock in a transaction on Monday, August 29th. The shares were sold at an average price of $1.01, for a total transaction of $50,500.00. Following the sale, the insider now directly owns 5 shares of the company’s stock, valued at $5.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Konstantinos Alataris purchased 127,389 shares of the stock in a transaction that occurred on Friday, August 19th. The shares were purchased at an average cost of $1.32 per share, for a total transaction of $168,153.48. The disclosure for this purchase can be found here. Insiders own 5.37% of the company’s stock.
An institutional investor recently raised its position in Zosano Pharma Corp. stock. Lombard Odier Asset Management USA Corp increased its position in shares of Zosano Pharma Corp. (NASDAQ:ZSAN) by 66.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 795,722 shares of the company’s stock after buying an additional 318,450 shares during the period. Lombard Odier Asset Management USA Corp owned 6.62% of Zosano Pharma Corp. worth $615,000 as of its most recent SEC filing. 35.89% of the stock is owned by institutional investors and hedge funds.
About Zosano Pharma Corp.
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Stock Ratings for Zosano Pharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corp. and related stocks with our FREE daily email newsletter.